Combined Detection Reagent Of Troponin I,Myoglobin And Creatine
Kinase Isoenzyme (Immunofluorescence Chromatography)
CTnI/MYO/CK-MB Overview
Troponin I/myoglobin/creatine kinase isoenzyme (cTnI/MYO/CK-MB)
includes the detection of the following three indicators: troponin
I (cTnI), myoglobin (MYO), creatine kinase Isoenzyme (CK-MB), the
combined detection of these three items is of great significance in
the early diagnosis of acute myocardial infarction (AMI) and other
acute myocardial diseases.
National Academy of Clinical Biochemical Sciences (NACB) Practice
Guidelines
All patients with suspected ACS should be tested for myocardial
necrosis markers
Troponin is the first choice marker for the diagnosis of myocardial
infarction
The combined application of myoglobin and specific myocardial
necrosis markers (such as cTnI/CK-MB) helps to rule out or diagnose
myocardial infarction more quickly
| | MYO | CK-MB | cTnI |
| molecular weight | 17.8KD | 86KD | 22.5KD |
| Rise time | 1-2h | 4-6h | 3-6h |
| Peak time | 6-9h | 24h | 12-16h |
| recovery time | 18-30h | 2-3d | 4-10d |
| Clinical value | 1.The most important indicator of early AMI exclusion
2. Diagnosis of AMI recurrence, the best index for evaluating the
effect of reperfusion treatment | 1.Estimate the size of the infarct or re-infarction
2. The most valuable markers of MI without ST-segment elevation | 1.The first choice marker for AMI diagnosis
2. Judge the infarct size and carry out risk stratification |
CTnI/MYO/CK-MB Clinical Significance
- Contribute to the early diagnosis and risk stratification of acute
coronary syndrome
- Judging the area of myocardial ischemia injury
- Differential diagnosis of various causes of chest pain
- Monitoring of myocardial injury caused by various reasons
- Evaluation of clinical efficacy of certain therapeutic drugs
| Possibility of outcome | |
| cTnI | CK-MB | MYO | Clinical possibility |
+ | + | + | It can basically diagnose myocardial infarction/myocardial injury,
and the occurrence time is within 12-24 hours; |
| + | + | - | It can basically be diagnosed as myocardial infarction/myocardial
injury, the detection time is more than 1 day, and the detection
window of MYO has passed |
| + | - | - | Myocardial infarction/myocardial injury has been onset for 2-3
days, and it is recommended to review after a few hours; |
| + | - | + | In patients with myocardial infarction/myocardial injury, the
detection time may exceed 3 days for symptoms, and the patient has
re-injury or enlarged infarct size; |
| - | + | + | Early myocardial infarction/myocardial injury/muscle injury, it is
recommended to review cTnI within 4-8 hours; |
- | - | + | 1. Early myocardial infarction/myocardial injury, it is recommended
to review cTnI within 4-8 hours; |
| 2. It may be caused by other injury diseases, such as creation,
skeletal muscle injury, liver and kidney disease; |
| - | + | - | 1. For minor myocardial damage, it is recommended to review cTnI
within 4-8 hours; |
| 2. It may be a non-myocardial injury disease, and the detection
time has passed the MYO window period; |
- | - | - | Myocardial infarction/myocardial injury is basically ruled out. If
it is highly suspected, it is recommended to review every 2-4
hours. |
cTnI/MYO/CK-MB Performance Index
| Detection range | sample size | Sample type | Test time |
| cTnI | MYO | CK-MB | 60μl | Whole blood / serum / plasma | 15min |
| 0.1~50ng/mL | 10~200ng/mL | 0.8~100ng/mL |
Application Department
Outpatient, emergency, physical examination center, cardiovascular,
ICU, chest pain center and other departments
CTnI/MYO/CK-MB Clinical Comparison
Company profile
Zhongxiu Science And Technology Co.,Ltd., is a high-tech enterprise
engaged in the research and development, production and operation
of in vitro diagnostic products. The in vitro diagnostic products
developed by the company cover POCT series, microbial series,
biochemical series and immune series reagents and supporting
instruments.
The company has always adhered to the core concept of "fast and
accurate, living up to life", committed to providing society with
excellent products and services, and contributing to the cause of
human health.
